Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Leases (2020 - 2025)

10x Genomics' Current Leases history spans 6 years, with the latest figure at $11.0 million for Q4 2025.

  • For Q4 2025, Current Leases rose 18.3% year-over-year to $11.0 million; the TTM value through Dec 2025 reached $11.0 million, up 18.3%, while the annual FY2025 figure was $11.0 million, 18.3% up from the prior year.
  • Current Leases for Q4 2025 was $11.0 million at 10x Genomics, up from $10.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $11.5 million in Q4 2023 and bottomed at $4.5 million in Q3 2021.
  • The 5-year median for Current Leases is $9.3 million (2023), against an average of $8.7 million.
  • The largest annual shift saw Current Leases soared 88.02% in 2022 before it decreased 19.4% in 2024.
  • A 5-year view of Current Leases shows it stood at $5.1 million in 2021, then soared by 76.13% to $9.0 million in 2022, then increased by 27.49% to $11.5 million in 2023, then dropped by 19.4% to $9.3 million in 2024, then increased by 18.3% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Current Leases are $11.0 million (Q4 2025), $10.5 million (Q3 2025), and $9.7 million (Q2 2025).